# Experiment 4: audit cards for real AI-generated reports

Computed by the program from each judge's extraction. Nothing here has been checked by a person yet.

## vitd: Does vitamin D supplementation reduce the risk of acute respiratory infections in adults?

### anthropic/claude-haiku-4.5

- Conclusion: Vitamin D supplementation does not consistently reduce the risk of acute respiratory infections in adults, although a possible small benefit may remain for people with severe vitamin D deficiency or for specific dosing regimens.
- References cited: 4; routes: 4; distinct sources in routes: 4
- Source resilience if all conditions hold: 2
- Interval with every condition unresolved: [0, 2]
- Minimal failure certificates (29): {U1}; {C2, 2024 systematic review and meta analysis of 43 rcts}; {2024 systematic review and meta analysis of 43 rcts, martineau 2017 individual participant data meta analysis of 25 rcts}; {C1, C3, 2024 systematic review focused on ari prevention}; {C1, C4, 2024 systematic review focused on ari prevention}; {C1, 2024 systematic review and meta analysis of 43 rcts, 2024 systematic review focused on ari prevention}; {C2, C3, C5}; {C2, C3, C6}; {C2, C3, U2}; {C2, C3, 2024 aggregate data meta analysis of 46 rcts}; {C2, C3, 2024 systematic review focused on ari prevention}; {C2, C4, C5} ...
- Single-condition bottlenecks: U1 (Meta-analyses and systematic reviews of RCTs provide valid evidence for population-level preventive effects)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 2

  - check C1 (The findings from trials including participants aged 0-95 years transfer to adults specifically): used by 1 route(s); if confirmed [0, 2], if rejected [0, 2]
  - check C2 (The baseline vitamin D concentrations and deficiency thresholds in the trials match clinically relevant definitions of severe deficiency): used by 2 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check C3 (The dosing regimens tested (including 400-1,200 IU daily) represent the relevant supplementation strategies for clinical practice): used by 1 route(s); if confirmed [0, 2], if rejected [0, 2]
  - check C4 (Seasonal variation in benefit (spring, autumn, winter) is generalizable across different geographic and climate contexts): used by 1 route(s); if confirmed [0, 2], if rejected [0, 2]
  - check C5 (The definition and measurement of acute respiratory infections is consistent across the included trials): used by 1 route(s); if confirmed [0, 2], if rejected [0, 2]
  - check C6 (The participants in these trials are representative of generally healthy working-age adults to whom the conclusion applies): used by 2 route(s); if confirmed [0, 2], if rejected [0, 2]
  - check U1 (Meta-analyses and systematic reviews of RCTs provide valid evidence for population-level preventive effects): used by 4 route(s); if confirmed [0, 2], if rejected [0, 0]
  - check U2 (Absence of statistical significance in pooled estimates indicates absence of clinically meaningful effect): used by 1 route(s); if confirmed [0, 2], if rejected [0, 2]

### openai/gpt-4.1

- Conclusion: Vitamin D supplementation does not consistently reduce the risk of acute respiratory infections (ARIs) in adults, although a possible small benefit remains for people with severe vitamin D deficiency or for specific dosing regimens.
- References cited: 4; routes: 3; distinct sources in routes: 4
- Source resilience if all conditions hold: 1
- Interval with every condition unresolved: [0, 1]
- Minimal failure certificates (9): {C1}; {U1}; {2024 systematic review and meta analysis springer unknown authors}; {C2, C4}; {C2, martineau 2017 individual participant data meta analysis}; {C4, 2024 aggregate data meta analysis medrxiv unknown authors}; {C4, 2024 systematic review and meta analysis pmc unknown authors}; {2024 aggregate data meta analysis medrxiv unknown authors, martineau 2017 individual participant data meta analysis}; {2024 systematic review and meta analysis pmc unknown authors, martineau 2017 individual participant data meta analysis}
- Single-condition bottlenecks: C1 (The populations, dosing regimens, and ARI definitions in the cited meta-analyses are sufficiently similar to the general adult population and supplementation practices addressed in the conclusion.), U1 (The meta-analyses included all relevant and high-quality randomized controlled trials up to their respective dates.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 1

  - check C1 (The populations, dosing regimens, and ARI definitions in the cited meta-analyses are sufficiently similar to the general adult population and supplementation practices addressed in the conclusion.): used by 2 route(s); if confirmed [0, 1], if rejected [0, 0]
  - check C2 (The lack of statistically significant effect in the recent meta-analyses reflects a true absence of clinically meaningful benefit, rather than limitations of study power or design.): used by 1 route(s); if confirmed [0, 1], if rejected [0, 1]
  - check C4 (Any possible benefit in severely deficient adults or with specific dosing regimens remains uncertain and requires further targeted trials.): used by 1 route(s); if confirmed [0, 1], if rejected [0, 1]
  - check U1 (The meta-analyses included all relevant and high-quality randomized controlled trials up to their respective dates.): used by 2 route(s); if confirmed [0, 1], if rejected [0, 0]

### qwen/qwen3-235b-a22b-2507

- Conclusion: Vitamin D supplementation does not consistently reduce the risk of acute respiratory infections (ARIs) in adults, although a possible small benefit remains for people with severe vitamin D deficiency or for specific dosing regimens.
- References cited: 4; routes: 4; distinct sources in routes: 4
- Source resilience if all conditions hold: 4
- Interval with every condition unresolved: [0, 4]
- Minimal failure certificates (34): {U1}; {C1, C3}; {C1, U2}; {C3, C4}; {C3, martineau 2017 meta analysis}; {C4, U2}; {U2, martineau 2017 meta analysis}; {C1, C2, C5}; {C1, C5, C6}; {C1, C5, 2024 systematic review and meta analysis springer}; {C1, C6, C7}; {C1, C6, 2024 systematic review and meta analysis pmc} ...
- Single-condition bottlenecks: U1 (The outcome of 'experiencing at least one ARI' is clinically meaningful and comparable across studies.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 2

  - check C1 (The effect of vitamin D supplementation on ARIs in children and older adults generalizes to generally healthy working-age adults.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C2 (The dosing regimens studied (e.g., daily 400–1,200 IU) are representative of typical supplementation patterns in the target population.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C3 (The definition and measurement of acute respiratory infections are consistent across the included studies.): used by 3 route(s); if confirmed [0, 4], if rejected [0, 1]
  - check C4 (Baseline vitamin D status in participants reflects clinically relevant deficiency levels (e.g., <25 nmol/L).): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C5 (The statistical methods used in the meta-analyses appropriately account for heterogeneity and risk of bias across trials.): used by 2 route(s); if confirmed [0, 4], if rejected [0, 2]
  - check C6 (The newer large trials included in the 2024 reviews are methodologically sound and representative of the population of interest.): used by 2 route(s); if confirmed [0, 4], if rejected [0, 2]
  - check C7 (The absence of a significant subgroup effect by baseline vitamin D status in the 2024 reviews applies to severely deficient individuals specifically.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check U1 (The outcome of 'experiencing at least one ARI' is clinically meaningful and comparable across studies.): used by 4 route(s); if confirmed [0, 4], if rejected [0, 0]

## creatine: Is long-term creatine supplementation safe for kidney function in healthy adults?

### anthropic/claude-haiku-4.5

- Conclusion: Long-term creatine supplementation appears safe for kidney function in healthy adults when used at standard doses, although it can modestly raise blood creatinine without indicating actual kidney injury.
- References cited: 5; routes: 5; distinct sources in routes: 5
- Source resilience if all conditions hold: 4
- Interval with every condition unresolved: [0, 4]
- Minimal failure certificates (18): {C1, C6}; {C1, U2}; {C1, 2023 review on creatine supplementation and kidney dysfunction}; {C1, 2025 systematic review and meta analysis on creatine and kidney function}; {C6, C7}; {C6, U1}; {C7, U2}; {C7, 2023 review on creatine supplementation and kidney dysfunction}; {C7, 2025 systematic review and meta analysis on creatine and kidney function}; {U1, U2}; {U1, 2023 review on creatine supplementation and kidney dysfunction}; {U1, 2025 systematic review and meta analysis on creatine and kidney function} ...
- Single-condition bottlenecks: none
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 2

  - check C1 (The user is a healthy adult with no pre-existing kidney disease): used by 4 route(s); if confirmed [0, 4], if rejected [0, 1]
  - check C2 (Creatine is used at standard doses, typically 3–5 g/day): used by 3 route(s); if confirmed [0, 4], if rejected [0, 2]
  - check C6 (Elevated serum creatinine from supplementation does not reflect actual kidney damage and should be interpreted with complementary measures): used by 1 route(s); if confirmed [0, 4], if rejected [0, 4]
  - check C7 (The study populations in references 1-5 are representative of the healthy adult population to which the conclusion applies): used by 4 route(s); if confirmed [0, 4], if rejected [0, 1]
  - check U1 (Absence of evidence of kidney harm in the studies reviewed constitutes sufficient evidence of safety): used by 4 route(s); if confirmed [0, 4], if rejected [0, 1]
  - check U2 (The distinction between elevated creatinine and actual kidney dysfunction is clinically meaningful and actionable): used by 1 route(s); if confirmed [0, 4], if rejected [0, 4]

### openai/gpt-4.1

- Conclusion: Long-term creatine supplementation appears safe for kidney function in healthy adults when used at standard doses.
- References cited: 5; routes: 5; distinct sources in routes: 5
- Source resilience if all conditions hold: 5
- Interval with every condition unresolved: [0, 5]
- Minimal failure certificates (5): {C1}; {C2}; {C3}; {C4}; {2023 narrative review unknown authors, 2025 safety review unknown authors, 2025 systematic review and meta analysis unknown authors, antonio 2019 systematic review and meta analysis, kreider 2017 issn position stand}
- Single-condition bottlenecks: C1 (The populations, doses, and durations studied in the cited reviews and studies are representative of healthy adults using standard creatine supplementation protocols.), C2 (The absence of observed kidney dysfunction in the cited studies is sufficient to infer safety for kidney function in healthy adults at standard doses.), C3 (The increase in serum creatinine observed with creatine supplementation does not reflect actual kidney injury in healthy adults.), C4 (The findings from studies with durations up to 60 months can be generalized to 'long-term' use as referenced in the conclusion.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 0

  - check C1 (The populations, doses, and durations studied in the cited reviews and studies are representative of healthy adults using standard creatine supplementation protocols.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]
  - check C2 (The absence of observed kidney dysfunction in the cited studies is sufficient to infer safety for kidney function in healthy adults at standard doses.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]
  - check C3 (The increase in serum creatinine observed with creatine supplementation does not reflect actual kidney injury in healthy adults.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]
  - check C4 (The findings from studies with durations up to 60 months can be generalized to 'long-term' use as referenced in the conclusion.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]

### qwen/qwen3-235b-a22b-2507

- Conclusion: Long-term creatine supplementation appears safe for kidney function in healthy adults when used at standard doses, although it can modestly raise blood creatinine—a marker that may falsely suggest reduced kidney function without indicating actual kidney injury.
- References cited: 5; routes: 6; distinct sources in routes: 5
- Source resilience if all conditions hold: 5
- Interval with every condition unresolved: [0, 5]
- Minimal failure certificates (33): {U1}; {C1, C2, C3, C4, C5}; {C1, C2, C3, C4, kreider 2017 position stand}; {C1, C2, C3, C5, 2025 safety review}; {C1, C2, C3, 2025 safety review, kreider 2017 position stand}; {C1, C2, C4, C5, 2023 review}; {C1, C2, C4, 2023 review, kreider 2017 position stand}; {C1, C2, C5, 2023 review, 2025 safety review}; {C1, C2, 2023 review, 2025 safety review, kreider 2017 position stand}; {C1, C3, C4, C5, 2025 meta analysis}; {C1, C3, C4, 2025 meta analysis, kreider 2017 position stand}; {C1, C3, C5, 2025 meta analysis, 2025 safety review} ...
- Single-condition bottlenecks: U1 (Standard doses of creatine supplementation (e.g., 3–5 g/day) do not cause structural or functional kidney damage in healthy adults over the long term.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 2

  - check C1 (The populations studied in the Antonio 2019 meta-analysis are representative of healthy adults using standard-dose creatine supplementation.): used by 1 route(s); if confirmed [0, 5], if rejected [0, 4]
  - check C2 (The populations studied in the 2025 meta-analysis are representative of healthy adults using standard-dose creatine supplementation.): used by 1 route(s); if confirmed [0, 5], if rejected [0, 4]
  - check C3 (The study cited in the 2023 review (comparing non-users with users up to 21 months) applies to healthy adults and uses standard creatine dosing protocols.): used by 1 route(s); if confirmed [0, 5], if rejected [0, 4]
  - check C4 (The broader safety data summarized in the 2025 safety review apply to healthy adults and cover doses and durations relevant to long-term use.): used by 1 route(s); if confirmed [0, 5], if rejected [0, 4]
  - check C5 (The International Society of Sports Nutrition position stand's assessment is based on evidence from healthy adults using creatine monohydrate at commonly studied doses (e.g., up to 30 g/day for five years).): used by 1 route(s); if confirmed [0, 5], if rejected [0, 4]
  - check U1 (Standard doses of creatine supplementation (e.g., 3–5 g/day) do not cause structural or functional kidney damage in healthy adults over the long term.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]

## lfp: Do lithium iron phosphate (LFP) home storage batteries last more than 6000 full cycles?

### anthropic/claude-haiku-4.5

- Conclusion: Some LFP home-storage batteries are specified to last more than 6,000 full-equivalent cycles, but this depends strongly on depth of discharge, temperature, charge rate, and the manufacturer's end-of-life definition.
- References cited: 5; routes: 2; distinct sources in routes: 5
- Source resilience if all conditions hold: 2
- Interval with every condition unresolved: [0, 2]
- Minimal failure certificates (48): {C1, C4}; {C1, C5}; {C1, C6}; {C1, deye se f12 product datasheet 2026}; {C1, goodwe lynx a g3 product datasheet 2026}; {C1, pylontech evolve lfp product datasheet 2025}; {C2, C4}; {C2, C5}; {C2, C6}; {C2, deye se f12 product datasheet 2026}; {C2, goodwe lynx a g3 product datasheet 2026}; {C2, pylontech evolve lfp product datasheet 2025} ...
- Single-condition bottlenecks: none
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 2

  - check C1 (The Wilhelm et al. 2018 study's findings on commercial lithium-iron-phosphate/graphite cells' cycle stability up to 10,000 FECs apply to home-storage battery products): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check C2 (The Wilhelm et al. 2018 estimate that a typical home-storage system operating for 20 years would experience about 6,000 FECs applies to the systems being evaluated): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check C3 (The Omar et al. 2014 experimental findings on LFP battery cycle life at different depths of discharge, temperatures, and charging rates apply to commercial home-storage products): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check C4 (Pylontech EVOLVE LFP's specification of more than 6,000 cycles at 90% depth of discharge and 25°C is accurate as stated in the datasheet): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check C5 (GoodWe Lynx A G3's specification of more than 6,000 cycles at 70% remaining capacity end-of-life criterion is accurate as stated in the datasheet): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check C6 (Deye SE-F12's specification of exactly 6,000 cycles is accurate as stated in the datasheet): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check C7 (The tested cells in Omar et al. 2014 are representative of LFP chemistry used in commercial home-storage batteries): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check U1 (The definition of 'full-equivalent cycle' used in the cited studies matches the definition used by the commercial manufacturers cited): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]

### openai/gpt-4.1

- Conclusion: High-quality LFP home batteries can be rated above 6,000 full-equivalent cycles, and some independent evidence indicates that LFP cells can exceed this level; nevertheless, buyers should compare the complete warranty test conditions—not chemistry alone—including depth of discharge, temperature, power rate, usable capacity at end of warranty, and calendar-life limit.
- References cited: 5; routes: 2; distinct sources in routes: 4
- Source resilience if all conditions hold: 2
- Interval with every condition unresolved: [0, 2]
- Minimal failure certificates (11): {C3}; {C4}; {C1, C2}; {C1, goodwe lynx a g3 datasheet}; {C1, pylontech evolve lfp datasheet}; {C2, omar 2014 laboratory study}; {C2, wilhelm 2018 laboratory and modeling study}; {goodwe lynx a g3 datasheet, omar 2014 laboratory study}; {goodwe lynx a g3 datasheet, wilhelm 2018 laboratory and modeling study}; {omar 2014 laboratory study, pylontech evolve lfp datasheet}; {pylontech evolve lfp datasheet, wilhelm 2018 laboratory and modeling study}
- Single-condition bottlenecks: C3 (The definition of 'full-equivalent cycle' and end-of-life threshold used in the studies and datasheets matches the one in the report's conclusion.), C4 (The operating conditions (depth of discharge, temperature, charge rate) in the cited studies and datasheets are comparable to those in typical home battery use.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 0

  - check C1 (The laboratory-tested cells in Wilhelm 2018 and Omar 2014 are representative of commercial LFP home-storage batteries.): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check C2 (The cycle-life specifications in the Pylontech, GoodWe, and Deye datasheets reflect actual product performance under typical home-storage conditions.): used by 1 route(s); if confirmed [0, 2], if rejected [0, 1]
  - check C3 (The definition of 'full-equivalent cycle' and end-of-life threshold used in the studies and datasheets matches the one in the report's conclusion.): used by 2 route(s); if confirmed [0, 2], if rejected [0, 0]
  - check C4 (The operating conditions (depth of discharge, temperature, charge rate) in the cited studies and datasheets are comparable to those in typical home battery use.): used by 2 route(s); if confirmed [0, 2], if rejected [0, 0]

### qwen/qwen3-235b-a22b-2507

- Conclusion: Yes, high-quality LFP home batteries can be rated above 6,000 full-equivalent cycles, and some independent evidence indicates that LFP cells can exceed this level; nevertheless, buyers should compare the complete warranty test conditions—not chemistry alone—including depth of discharge, temperature, power rate, usable capacity at end of warranty, and calendar-life limit.
- References cited: 5; routes: 3; distinct sources in routes: 5
- Source resilience if all conditions hold: 3
- Interval with every condition unresolved: [0, 3]
- Minimal failure certificates (145): {U3}; {C10, U2}; {C11, U2}; {C7, U2}; {C8, U2}; {C9, U2}; {U1, U2}; {U2, deye sana energy datasheet}; {U2, goodwe lynx a g3 datasheet}; {U2, pylontech evolve lfp datasheet}; {C1, C10, C5}; {C1, C10, C6} ...
- Single-condition bottlenecks: U3 (The definition of 'home-storage battery' in the studies and datasheets matches the one in the conclusion.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 3

  - check C1 (The tested LFP cells in Wilhelm et al. 2018 are representative of those used in home-storage batteries.): used by 1 route(s); if confirmed [0, 3], if rejected [0, 2]
  - check C10 (The stated specification (>6,000 cycles with 70% end-of-life threshold) in the GoodWe datasheet reflects achievable real-world performance under test conditions.): used by 1 route(s); if confirmed [0, 3], if rejected [0, 2]
  - check C11 (The Deye/SANA Energy battery specification (exactly 6,000 cycles) is representative of alternative LFP products in the market.): used by 1 route(s); if confirmed [0, 3], if rejected [0, 2]
  - check C2 (The operating conditions (depth of discharge, temperature, charge rate) in Wilhelm et al. 2018 match those claimed in the conclusion.): used by 1 route(s); if confirmed [0, 3], if rejected [0, 2]
  - check C3 (The end-of-life capacity threshold (80%) in Wilhelm et al. 2018 is consistent with the warranty conditions of commercial products.): used by 1 route(s); if confirmed [0, 3], if rejected [0, 2]
  - check C4 (The cycle model and calendar ageing estimates in Wilhelm et al. 2018 apply to real-world home-storage usage patterns over 20 years.): used by 1 route(s); if confirmed [0, 3], if rejected [0, 2]
  - check C5 (The LFP cells tested in Omar et al. 2014 are representative of those used in home-storage batteries.): used by 1 route(s); if confirmed [0, 3], if rejected [0, 2]
  - check C6 (The depth of discharge (80% and 20%), temperature (25°C and 40°C), and charge rates in Omar et al. 2014 are relevant to typical home-storage operation.): used by 1 route(s); if confirmed [0, 3], if rejected [0, 2]

## fasting: Does intermittent fasting produce more weight loss than continuous calorie restriction in adults?

### anthropic/claude-haiku-4.5

- Conclusion: Intermittent fasting does not consistently produce more weight loss than continuous calorie restriction in adults, and when energy intake is comparable, both approaches generally yield similar weight loss, although alternate-day fasting may provide a small additional short-term advantage.
- References cited: 5; routes: 6; distinct sources in routes: 5
- Source resilience if all conditions hold: 5
- Interval with every condition unresolved: [0, 5]
- Minimal failure certificates (24): {U1}; {C1, C4}; {C1, C5}; {C1, 2018 systematic review and meta analysis of rcts on intermittent vs continuous energy restriction}; {C1, 2024 systematic review and meta analysis of 10 rcts on fasting vs continuous caloric restriction}; {C1, yu et al 2025 systematic review and network meta analysis of 99 rcts}; {C2, C3, 2018 systematic review and meta analysis of rcts on intermittent vs continuous energy restriction}; {C3, U2, yu et al 2025 systematic review and network meta analysis of 99 rcts}; {C2, C3, C4, U2}; {C2, C3, C5, U2}; {C2, C3, U2, 2024 systematic review and meta analysis of 10 rcts on fasting vs continuous caloric restriction}; {C2, C6, 2018 systematic review and meta analysis of rcts on intermittent vs continuous energy restriction, allaf et al 2021 cochrane systematic review} ...
- Single-condition bottlenecks: U1 (Systematic reviews and meta-analyses of RCTs provide valid evidence for drawing conclusions about the comparative effectiveness of weight loss interventions)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 2

  - check C1 (The trials included in the systematic reviews are representative of real-world weight loss outcomes in adults): used by 5 route(s); if confirmed [0, 5], if rejected [0, 1]
  - check C2 (The modest differences in weight loss (0.94-1.29 kg) reported are clinically meaningful or not meaningful as intended by the conclusion): used by 2 route(s); if confirmed [0, 5], if rejected [0, 3]
  - check C3 (Short-term advantages (3-6 months) do not translate to long-term superiority of intermittent fasting): used by 2 route(s); if confirmed [0, 5], if rejected [0, 3]
  - check C4 (When total calorie reduction is matched between intermittent fasting and continuous restriction, the populations, adherence rates, and other variables are sufficiently comparable): used by 1 route(s); if confirmed [0, 5], if rejected [0, 5]
  - check C5 (The apparent short-term advantage of some fasting regimens reflects greater energy reduction or adherence rather than a unique metabolic effect of fasting itself): used by 1 route(s); if confirmed [0, 5], if rejected [0, 5]
  - check C6 (Weight regain at 4-6 months reported in reference 5 is representative of longer-term outcomes for intermittent fasting): used by 1 route(s); if confirmed [0, 5], if rejected [0, 4]
  - check U1 (Systematic reviews and meta-analyses of RCTs provide valid evidence for drawing conclusions about the comparative effectiveness of weight loss interventions): used by 6 route(s); if confirmed [0, 5], if rejected [0, 0]
  - check U2 (Statistical significance or lack thereof is an appropriate criterion for determining whether one weight loss method is superior to another): used by 2 route(s); if confirmed [0, 5], if rejected [0, 3]

### openai/gpt-4.1

- Conclusion: Intermittent fasting does not consistently produce more weight loss than continuous calorie restriction in adults; when energy intake is comparable, both approaches generally yield similar weight loss, although alternate-day fasting may provide a small additional short-term advantage.
- References cited: 5; routes: 5; distinct sources in routes: 5
- Source resilience if all conditions hold: 5
- Interval with every condition unresolved: [0, 5]
- Minimal failure certificates (6): {C1}; {C2}; {C3}; {C4}; {U1}; {allaf 2021 cochrane review, bmc endocrine disorders 2018 meta analysis, int j behav nutr phys act 2024 network meta analysis, obesity 2024 systematic review and meta analysis, yu 2025 bmj network meta analysis}
- Single-condition bottlenecks: C1 (The populations, interventions, and comparators in the cited trials are sufficiently similar to the general adult population considering weight loss strategies.), C2 (The durations of the trials are long enough to assess meaningful differences in weight loss between intermittent fasting and continuous calorie restriction.), C3 (The calorie intake in the intermittent fasting and continuous restriction arms is comparable in the relevant studies.), C4 (The adherence rates in the studies reflect what would be expected in real-world settings.), U1 (Weight loss is the primary and sufficient outcome for evaluating the superiority of one dietary strategy over another for adults.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 1

  - check C1 (The populations, interventions, and comparators in the cited trials are sufficiently similar to the general adult population considering weight loss strategies.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]
  - check C2 (The durations of the trials are long enough to assess meaningful differences in weight loss between intermittent fasting and continuous calorie restriction.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]
  - check C3 (The calorie intake in the intermittent fasting and continuous restriction arms is comparable in the relevant studies.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]
  - check C4 (The adherence rates in the studies reflect what would be expected in real-world settings.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]
  - check U1 (Weight loss is the primary and sufficient outcome for evaluating the superiority of one dietary strategy over another for adults.): used by 5 route(s); if confirmed [0, 5], if rejected [0, 0]

### qwen/qwen3-235b-a22b-2507

- Conclusion: Intermittent fasting does not consistently produce more weight loss than continuous calorie restriction in adults; when energy intake is comparable, both approaches generally yield similar weight loss, although alternate-day fasting may provide a small additional short-term advantage.
- References cited: 5; routes: 4; distinct sources in routes: 5
- Source resilience if all conditions hold: 4
- Interval with every condition unresolved: [0, 4]
- Minimal failure certificates (42): {U1}; {U2}; {C1, C3, U3}; {C1, C4, U3}; {C1, U3, allaf et al cochrane 2021 review}; {C1, U3, bmc endocrine disorders 2018 meta analysis}; {C3, U3, oi ying yu et al 2025 meta analysis}; {C4, U3, oi ying yu et al 2025 meta analysis}; {U3, allaf et al cochrane 2021 review, oi ying yu et al 2025 meta analysis}; {U3, bmc endocrine disorders 2018 meta analysis, oi ying yu et al 2025 meta analysis}; {C1, C2, C3, C5}; {C1, C2, C3, ijbnpa 2024 network meta analysis} ...
- Single-condition bottlenecks: U1 (Weight loss outcomes from clinical trials generalize to the broader adult population considering weight-loss strategies.), U2 (The definition of 'intermittent fasting' and 'continuous calorie restriction' is consistent across all included studies in the cited reviews.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 3

  - check C1 (The trials in the Oi-Ying Yu et al. 2025 meta-analysis are representative of adult populations seeking weight loss and use comparable energy intake between intermittent and continuous restriction.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C2 (The 2024 Obesity meta-analysis includes trials where fasting and continuous restriction were matched for total caloric intake over time.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C3 (The Cochrane 2021 review includes trials with sufficient duration and adherence to detect differences in weight loss between intermittent fasting and continuous restriction.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C4 (The BMC Endocrine Disorders 2018 meta-analysis compares intermittent and continuous energy restriction under isocaloric conditions.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C5 (The IJBNPA 2024 network meta-analysis reflects real-world adherence patterns and includes trials with accurate reporting of energy intake.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check U1 (Weight loss outcomes from clinical trials generalize to the broader adult population considering weight-loss strategies.): used by 4 route(s); if confirmed [0, 4], if rejected [0, 0]
  - check U2 (The definition of 'intermittent fasting' and 'continuous calorie restriction' is consistent across all included studies in the cited reviews.): used by 4 route(s); if confirmed [0, 4], if rejected [0, 0]
  - check U3 (Short-term weight loss differences are indicative of long-term outcomes when adherence is maintained.): used by 2 route(s); if confirmed [0, 4], if rejected [0, 2]

## heatpump: Do domestic heat pumps reduce heating-related CO2 emissions compared with gas boilers in the UK?

### anthropic/claude-haiku-4.5

- Conclusion: Domestic heat pumps generally reduce heating-related CO₂ emissions compared with gas boilers in the UK, although the size of the reduction depends on heat-pump type, seasonal efficiency, electricity carbon intensity, refrigerant impacts, and whether manufacture and installation are included.
- References cited: 6; routes: 5; distinct sources in routes: 4
- Source resilience if all conditions hold: 4
- Interval with every condition unresolved: [0, 4]
- Minimal failure certificates (20): {C1, U1}; {C1, U2}; {U1, carbon brief 2024 uk electricity analysis}; {U2, carbon brief 2024 uk electricity analysis}; {C1, C3, C4, C5}; {C1, C3, C4, ref1}; {C1, C3, C5, sevindik et al 2021 ucl hybrid heat pump lifecycle assessment}; {C1, C3, ref1, sevindik et al 2021 ucl hybrid heat pump lifecycle assessment}; {C1, C4, C5, sevindik et al 2021 ucl lifecycle assessment}; {C1, C4, ref1, sevindik et al 2021 ucl lifecycle assessment}; {C1, C5, sevindik et al 2021 ucl hybrid heat pump lifecycle assessment, sevindik et al 2021 ucl lifecycle assessment}; {C1, ref1, sevindik et al 2021 ucl hybrid heat pump lifecycle assessment, sevindik et al 2021 ucl lifecycle assessment} ...
- Single-condition bottlenecks: none
- References whose study could not be identified (kept separate): [1]
- Unstated premises proposed: 3

  - check C1 (The 84% emissions reduction in 2024 and comparison with 2014 applies to UK household heating contexts with current electricity grid composition): used by 1 route(s); if confirmed [1, 4], if rejected [0, 3]
  - check C3 (The UCL lifecycle assessment carbon intensities (0.111 kg CO₂e/kWh for air-source, 0.097 for ground-source, 0.241 for gas boiler) apply to UK conditions and current technology): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C4 (The 30% greenhouse-gas emissions reduction over 20 years applies to the specific hybrid heat pump and condensing gas boiler systems compared): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C5 (The UK lifecycle study reporting up to 6% CO₂-equivalent savings for air-source and 36% for water-source systems reflects conditions that are less favorable than current UK electricity and technology conditions): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check U1 (The lifecycle assessment studies adequately account for all relevant emissions sources (manufacturing, installation, operation, refrigerant leakage, end-of-life) to enable valid comparison): used by 3 route(s); if confirmed [0, 4], if rejected [0, 1]
  - check U2 (The gas boiler baseline (200-215 g CO₂/kWh) is representative of typical UK gas boiler systems being replaced): used by 3 route(s); if confirmed [0, 4], if rejected [0, 1]

### openai/gpt-4.1

- Conclusion: Domestic heat pumps generally reduce heating-related CO₂ emissions compared with gas boilers in the UK, although the size of the reduction depends on several factors.
- References cited: 6; routes: 3; distinct sources in routes: 5
- Source resilience if all conditions hold: 3
- Interval with every condition unresolved: [0, 3]
- Minimal failure certificates (15): {C3}; {C5}; {U1}; {C1, C2}; {C1, carbon brief 2025 analysis of uk electricity carbon intensity}; {C1, uk collaborative centre for housing evidence 2025 analysis}; {C2, C4}; {C2, selman sevindik et al 2021 ucl hybrid heat pump vs gas boiler assessment}; {C2, selman sevindik et al 2021 ucl lifecycle assessment}; {C4, carbon brief 2025 analysis of uk electricity carbon intensity}; {C4, uk collaborative centre for housing evidence 2025 analysis}; {carbon brief 2025 analysis of uk electricity carbon intensity, selman sevindik et al 2021 ucl hybrid heat pump vs gas boiler assessment, the independent 2026 summary article unknown underlying primary study} ...
- Single-condition bottlenecks: C3 (The seasonal performance factors (efficiency) of heat pumps in the studies are typical of real-world UK installations.), C5 (The operational and lifecycle emissions reductions found in the cited studies are transferable to the general UK domestic context.), U1 (Reducing heating-related CO₂ emissions is a desirable or relevant goal for UK domestic heating policy or consumer choice.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 1

  - check C1 (The heat pumps and gas boilers assessed in the cited studies are representative of those currently installed in UK homes.): used by 2 route(s); if confirmed [0, 3], if rejected [0, 1]
  - check C2 (The carbon intensity of UK electricity in the cited studies matches or is relevant to current and near-future UK conditions.): used by 2 route(s); if confirmed [0, 3], if rejected [0, 1]
  - check C3 (The seasonal performance factors (efficiency) of heat pumps in the studies are typical of real-world UK installations.): used by 3 route(s); if confirmed [0, 3], if rejected [0, 0]
  - check C4 (The lifecycle assessments include all relevant emissions sources (operation, manufacture, refrigerants, etc.) in a comparable way for both heat pumps and gas boilers.): used by 2 route(s); if confirmed [0, 3], if rejected [0, 1]
  - check C5 (The operational and lifecycle emissions reductions found in the cited studies are transferable to the general UK domestic context.): used by 3 route(s); if confirmed [0, 3], if rejected [0, 0]
  - check U1 (Reducing heating-related CO₂ emissions is a desirable or relevant goal for UK domestic heating policy or consumer choice.): used by 3 route(s); if confirmed [0, 3], if rejected [0, 0]

### qwen/qwen3-235b-a22b-2507

- Conclusion: Domestic heat pumps generally reduce heating-related CO₂ emissions compared with gas boilers in the UK, although the size of the reduction depends on several factors.
- References cited: 8; routes: 4; distinct sources in routes: 4
- Source resilience if all conditions hold: 4
- Interval with every condition unresolved: [0, 4]
- Minimal failure certificates (31): {C6}; {C1, C2}; {C1, C5}; {C1, U1}; {C1, carbon brief 2025 uk electricity analysis}; {C5, U2}; {C5, ref10}; {C2, C4, U2}; {C2, C4, ref10}; {C2, U2, U3}; {C2, U3, ref10}; {C4, U1, U2} ...
- Single-condition bottlenecks: C6 (The comparison between heating systems includes the same functional unit (e.g., per kWh of useful heat delivered).)
- References whose study could not be identified (kept separate): [10]
- Unstated premises proposed: 3

  - check C1 (The seasonal coefficient of performance (SCOP) of the heat pump is sufficient to maintain low electricity consumption relative to heat output.): used by 3 route(s); if confirmed [0, 4], if rejected [0, 1]
  - check C2 (The UK electricity grid carbon intensity in the time and context of the analysis matches or is similar to the values used in the cited studies (e.g., 2024 levels).): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C3 (The heat pump is correctly sized and installed, and operates with appropriate flow temperatures and building insulation levels.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C4 (Manufacturing, refrigerant leakage, and infrastructure emissions for heat pumps are within the ranges assumed in the lifecycle studies cited.): used by 2 route(s); if confirmed [0, 4], if rejected [0, 2]
  - check C5 (The gas boiler being compared is a standard condensing gas boiler with typical efficiency and emissions characteristics in the UK context.): used by 3 route(s); if confirmed [0, 4], if rejected [0, 1]
  - check C6 (The comparison between heating systems includes the same functional unit (e.g., per kWh of useful heat delivered).): used by 4 route(s); if confirmed [0, 4], if rejected [0, 0]
  - check U1 (The electricity carbon intensity used in the Carbon Brief analysis (ref 14 and 6) is representative of the national average for household heating use over the year.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check U2 (The seasonal performance factor (SPF) of 3.0 mentioned in the UK housing analysis (ref 10) is achievable in real-world UK domestic settings.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]

## melatonin: Does melatonin improve sleep quality in adults with chronic insomnia?

### anthropic/claude-haiku-4.5

- Conclusion: Melatonin may produce small improvements in some sleep measures, but evidence does not establish a clinically important improvement in overall sleep quality for adults with chronic insomnia, and major guidelines therefore recommend against routine use.
- References cited: 8; routes: 4; distinct sources in routes: 8
- Source resilience if all conditions hold: 4
- Interval with every condition unresolved: [0, 4]
- Minimal failure certificates (241): {U1}; {C1, C3, C5, C7}; {C1, C3, C5, american academy of sleep medicine 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia in adults}; {C1, C3, C5, national center for complementary and integrative health updated resource on sleep disorders and complementary health approaches}; {C1, C3, C6, C7}; {C1, C3, C6, american academy of sleep medicine 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia in adults}; {C1, C3, C6, national center for complementary and integrative health updated resource on sleep disorders and complementary health approaches}; {C1, C3, C7, 2022 systematic review and meta analysis of melatonin and ramelteon for insomnia in older adults}; {C1, C3, C7, american academy of family physicians 2021 review of melatonin for insomnia in older adults}; {C1, C3, 2022 systematic review and meta analysis of melatonin and ramelteon for insomnia in older adults, american academy of sleep medicine 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia in adults}; {C1, C3, 2022 systematic review and meta analysis of melatonin and ramelteon for insomnia in older adults, national center for complementary and integrative health updated resource on sleep disorders and complementary health approaches}; {C1, C3, american academy of family physicians 2021 review of melatonin for insomnia in older adults, american academy of sleep medicine 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia in adults} ...
- Single-condition bottlenecks: U1 (Lack of clinically important improvement in overall sleep quality is a sufficient basis for recommending against routine use of a treatment)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 2

  - check C1 (The findings from studies of melatonin in adults with chronic insomnia transfer to the general adult population seeking treatment for chronic insomnia): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C2 (Improvements in sleep-onset latency alone constitute 'small improvements in some sleep measures' rather than clinically important overall sleep quality improvement): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C3 (The 2013 meta-analysis (ref 3) findings on primary sleep disorders do not represent reliable treatment effects specifically for chronic insomnia in adults): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C4 (The 2021 meta-analysis (ref 4) findings from diverse medical conditions do not represent reliable treatment effects for chronic insomnia specifically): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C5 (Findings from prolonged-release melatonin in adults aged 55+ do not apply to immediate-release, over-the-counter melatonin in the general adult population): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C6 (Findings from older adults do not generalize to the broader adult population with chronic insomnia): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C7 (Major clinical guidelines (AASM, NCCIH, VA/DoD) represent current authoritative guidance on melatonin use for chronic insomnia): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check U1 (Lack of clinically important improvement in overall sleep quality is a sufficient basis for recommending against routine use of a treatment): used by 4 route(s); if confirmed [0, 4], if rejected [0, 0]

### openai/gpt-4.1

- Conclusion: Melatonin may produce small improvements in some sleep measures, but evidence does not establish a clinically important improvement in overall sleep quality for adults with chronic insomnia; major guidelines therefore recommend against routine use.
- References cited: 8; routes: 3; distinct sources in routes: 8
- Source resilience if all conditions hold: 3
- Interval with every condition unresolved: [0, 3]
- Minimal failure certificates (29): {C1}; {C2}; {C5}; {U1}; {C3, C4}; {C3, 2020 systematic review and network meta analysis of insomnia interventions}; {C3, 2022 systematic review and meta analysis of melatonin for chronic insomnia}; {C3, american academy of sleep medicine 2017 clinical practice guideline}; {C3, nccih 2026 summary of reviews and us guidelines}; {C4, 2021 systematic review and meta analysis of melatonin supplementation on sleep quality, 2022 systematic review and meta analysis of melatonin ramelteon for insomnia in older adults}; {C4, 2021 systematic review and meta analysis of melatonin supplementation on sleep quality, trials of prolonged release melatonin in adults aged 55 as summarized by aafp 2021}; {C4, 2022 systematic review and meta analysis of melatonin ramelteon for insomnia in older adults, ferracioli oda 2013 meta analysis of melatonin for primary sleep disorders} ...
- Single-condition bottlenecks: C1 (The populations, doses, and formulations studied in the cited trials and reviews are representative of adults with chronic insomnia in general clinical practice.), C2 (The sleep quality measures used in the cited studies are valid indicators of clinically important improvement.), C5 (Improvements in sleep-onset latency or total sleep time without improvement in overall sleep quality are not clinically important for adults with chronic insomnia.), U1 (A clinically important improvement in overall sleep quality is necessary for recommending routine use of melatonin in adults with chronic insomnia.)
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 1

  - check C1 (The populations, doses, and formulations studied in the cited trials and reviews are representative of adults with chronic insomnia in general clinical practice.): used by 3 route(s); if confirmed [0, 3], if rejected [0, 0]
  - check C2 (The sleep quality measures used in the cited studies are valid indicators of clinically important improvement.): used by 3 route(s); if confirmed [0, 3], if rejected [0, 0]
  - check C3 (Findings from studies including children, adolescents, older adults, or populations with diverse medical conditions do not generalize to the general adult population with chronic insomnia.): used by 2 route(s); if confirmed [0, 3], if rejected [0, 1]
  - check C4 (Guideline recommendations are based on comprehensive and up-to-date reviews of the evidence.): used by 1 route(s); if confirmed [0, 3], if rejected [0, 2]
  - check C5 (Improvements in sleep-onset latency or total sleep time without improvement in overall sleep quality are not clinically important for adults with chronic insomnia.): used by 3 route(s); if confirmed [0, 3], if rejected [0, 0]
  - check U1 (A clinically important improvement in overall sleep quality is necessary for recommending routine use of melatonin in adults with chronic insomnia.): used by 3 route(s); if confirmed [0, 3], if rejected [0, 0]

### qwen/qwen3-235b-a22b-2507

- Conclusion: Melatonin may produce small improvements in some sleep measures, but evidence does not establish a clinically important improvement in overall sleep quality for adults with chronic insomnia; major guidelines therefore recommend against routine use.
- References cited: 8; routes: 4; distinct sources in routes: 8
- Source resilience if all conditions hold: 4
- Interval with every condition unresolved: [0, 4]
- Minimal failure certificates (180): {C2, C8}; {C2, U2}; {C2, american academy of sleep medicine 2017 clinical practice guideline}; {C2, national center for complementary and integrative health 2026 report on sleep disorders}; {C1, C6, C8}; {C1, C6, U2}; {C1, C6, american academy of sleep medicine 2017 clinical practice guideline}; {C1, C6, national center for complementary and integrative health 2026 report on sleep disorders}; {C1, C7, C8}; {C1, C7, U2}; {C1, C7, american academy of sleep medicine 2017 clinical practice guideline}; {C1, C7, national center for complementary and integrative health 2026 report on sleep disorders} ...
- Single-condition bottlenecks: none
- References whose study could not be identified (kept separate): none
- Unstated premises proposed: 2

  - check C1 (The populations in the studies cited (refs 1, 2, 3, 4) are representative of adults with chronic insomnia.): used by 2 route(s); if confirmed [0, 4], if rejected [0, 2]
  - check C2 (The melatonin formulations and doses used in the studies (refs 1, 2, 3, 4) are comparable to those used by the general adult population (e.g., immediate-release, over-the-counter).): used by 3 route(s); if confirmed [0, 4], if rejected [0, 1]
  - check C3 (The outcome measures of sleep quality in the studies (refs 1, 2, 3, 4) align with clinically meaningful improvements in overall sleep quality.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C5 (The positive results in populations with diverse medical conditions (ref 4) do not generalize to adults with chronic insomnia alone.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C6 (The results from studies on older adults (refs 5, 6) do not generalize to the general adult population with chronic insomnia.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C7 (The inclusion of ramelteon in some studies (ref 5) does not confound the assessment of melatonin's effects.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check C8 (The clinical guidelines cited (refs 7, 8) are based on current and comprehensive evidence evaluations relevant to adults with chronic insomnia.): used by 1 route(s); if confirmed [0, 4], if rejected [0, 3]
  - check U1 (Improvements in sleep measures such as sleep-onset latency or total sleep time are not sufficient to constitute clinically important improvement in overall sleep quality.): used by 2 route(s); if confirmed [0, 4], if rejected [0, 2]

## Agreement across judges

| report | refs | tau_S per judge | bottleneck found per judge |
|---|---|---|---|
| vitd | 4 | 2, 1, 4 | yes, yes, yes |
| creatine | 5 | 4, 5, 5 | no, yes, yes |
| lfp | 5 | 2, 2, 3 | no, yes, yes |
| fasting | 5 | 5, 5, 4 | yes, yes, yes |
| heatpump | 8 | 4, 3, 4 | no, yes, yes |
| melatonin | 8 | 4, 3, 4 | yes, yes, no |
